Af­ter No­var­tis walks on last STING drug, Chi­nook spits out or­phan Aduro as­sets

In Au­gust, Chi­nook merged with the strug­gling Aduro to take on the com­pa­ny’s pipeline pro­grams for kid­ney dis­ease re­search. Mon­day, Chi­nook an­nounced that Aduro will take on a new name: Sairopa.

The com­pa­ny an­nounced a par­tial sale to Van Herk In­vest­ments, a Eu­ro­pean life sci­ence in­vestor, to cre­ate a new com­pa­ny called Sairopa that will fo­cus on the R&D of non-re­nal mon­o­clon­al an­ti­bod­ies that were gen­er­at­ed through Aduro’s B-Se­lect plat­form. As a part of the deal, Chi­nook will re­lin­quish con­trol of all the as­sets it ac­quired from Aduro.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER